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Structured abstract 
 
Objectives: To analyse enrolment to interventional trials during the first wave of the 
coronavirus 2019 (COVID-19) pandemic in England and describe the barriers to 
successful recruitment in the circumstance of a further wave or future pandemics. 
Design: We analysed registered interventional COVID-19 trial data and concurrently 
did a prospective observational study of hospitalised patients with COVID-19 who 
were being assessed for eligibility to one of the RECOVERY, C19-ACS or SIMPLE 
trials.  
Setting: Interventional COVID-19 trial data were analysed from the clinicaltrials.gov 
and ISRCTN databases on July 12, 2020. The patient cohort was taken from 5 
centres in a respiratory NIHR network. Population and modelling data were taken 
from published reports from the UK government and MRC biostatistics unit. 
Participants: 2,082 consecutive admitted patients with laboratory-confirmed SARS-
CoV-2 infection from March 27, 2020 were included. 
Main outcome measures: Proportions enrolled, and reasons for exclusion from the 
aforementioned trials. Comparisons of trial recruitment targets with estimated 
feasible recruitment numbers. 
Results: Analysis of trial registration data for COVID-19 treatment studies enrolling 
in England showed that by July 12, 2020, 29,142 participants were needed. In the 
observational study, 430 (20.7%) proceeded to randomisation. 82 (3.9%) declined 
participation, 699 (33.6%) were excluded on clinical grounds, 363 (17.4%) were 
medically fit for discharge, and 153 (7.3%) were receiving palliative care. With 
111,037 people hospitalised with COVID-19 in England by July 12, 2020, we 
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determine that 22,985 people were potentially suitable for trial enrolment. We 
estimate a UK hospitalisation rate of 2.38%, and that another 1.25 million infections 
would be required to meet recruitment targets of ongoing trials. 
Conclusions: Feasible recruitment rates, study design, and proliferation of trials can 
limit the number, and size, that will successfully complete recruitment. We consider 
that fewer, more appropriately designed trials, prioritising cooperation between 
centres would maximise productivity in a further wave. 
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Strengths and limitations of this study 
• We comprehensively analysed clinical trial registry data to quantify the 
number of participants required to successfully complete enrolment to 
interventional COVID-19 trials based in England in the first wave of the 
pandemic. 
• We simultaneously performed a large, prospective, observational cohort study 
of 2,082 people hospitalised with COVID-19 to report recruitment rates across 
a range of secondary and tertiary centres and characterise reasons for trial 
exclusion. 
• Using government data on COVID-19 hospitalisations, we consider the 
differences between the trials community’s aspirations and delivery, and how 
this might inform our strategy in the event of a second wave. 
• Our analysis is restricted to two registry databases and includes trials that 
started recruiting late in the first wave; we therefore likely underestimate the 
recruitment target and overestimate the number of eligible patients. 
• Our analysis is limited to data based in England and, while we consider global 
trials, our conclusions may not be representative of, or readily translatable to, 
international cohorts. 
  
 - 8 - 
Introduction 
 
Unless a successful vaccination programme is deployed, the greatest need for 
coronavirus disease 2019 (COVID-19) remains effective treatments. This presents a 
substantial challenge. Ostensibly, the response from the experimental medicine 
community to the first wave has been robust, with more than 1,970 clinical trials 
planned, recruiting, or completed, at the time of writing.1 This has enabled enrolment 
of patients to trials of drugs with known safety profiles – including lopinavir,2 
remdesivir,3 4 hydroxychloroquine5 6 and tocilizumab7 – and led to positive results, 
such as the 12.1% absolute risk reduction in mortality among ventilated patients 
treated with dexamethasone.8  
 
However, while many of these trials have been pragmatic in terms of selection 
criteria, the proportion of hospitalised COVID-19 patients being recruited to clinical 
trials is lower than might have been anticipated; the authors of the RECOVERY trial 
recently estimated a 10% recruitment rate in the UK.9 Meanwhile, in areas where 
public health measures have limited viral transmission, trials have terminated early 
on account of under recruitment.10 11 With mounting concern about an ensuing 
second wave of infection,12 13 it is increasingly important to learn lessons from the 
first, and consider the number, size and design of clinical trials that can feasibly be 
completed. 
 
We hypothesised that the proliferation of SARS-CoV-2 interventional studies during 
the pandemic and under recognised barriers to recruitment of COVID-19 patients led 
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to unachievable recruitment targets in England. We used data from clinical trial 
registry databases to quantify recruitment targets and concurrently studied 
recruitment rates, including reasons for exclusion, across 5 centres enrolling patients 
at the peak of the first wave of the pandemic. In conjunction with publicly available 
data from the UK government, we consider the differences between the trials 
community’s aspirations and delivery, and how this might inform our strategy if there 
were a second wave. 
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Methods 
 
Establishing recruitment targets for registered trials during first wave 
COVID-19 clinical studies registered on clinicaltrials.gov or the International 
Standard Randomized Controlled Trial Number (ISRCTN) databases were identified 
and study data downloaded on July 12, 2020. Data for trials based in England, 
multinational trials with centres in England, and global trials were extracted in turn. 
Cross-registered studies were identified and accounted for once in the analysis. A 
manual review determined whether sponsors were academic, non-academic or 
mixed. Trials were excluded if they were labelled as terminated, withdrawn or 
suspended. Data for interventional trials examining treatment and prevention were 
documented, but only trials of COVID-19 treatments were used in the analysis. 
Analyses were performed using RStudio Version 1.2.5042. 
 
Observational study of recruitment of hospitalised patients 
We performed a prospective observational study of 2,082 consecutive patients with 
SARS-CoV-2 infection at 5 hospitals affiliated to the NIHR-Translational Research 
Collaboration with representation from secondary and tertiary centres: Cambridge 
University Hospitals NHS Foundation Trust (CUHFT), Cambridge; Imperial College 
Healthcare, University College Hospital and King’s College Hospitals, London; and 
University Hospital of North Tees, Middlesbrough. Subjects were admitted and 
eligibility assessed for: RECOVERY (ISRCTN50189673), C19-ACS (NCT04333407) 
or SIMPLE (NCT04292730/NCT04292899). CUHFT local R&D approval was 
undertaken. 
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Demographic and clinical data were collected by contemporaneous review of 
potential participants’ case notes. A categorical approach subdivided primary 
reasons subjects were not enrolled into: (a) clinical grounds (screening or treating 
physician judgement that comorbidity or other reason for admission was more critical 
to patient outcome than COVID-19), (b) medically fit for discharge, (c) receiving end 
of life care, (d) lack of capacity, (e) patient refusal, (f) interactions with trial drugs, or 
(g) already on mechanical ventilation. Though already being on mechanical 
intervention was not an exclusion criterion for RECOVERY, patients categorised as 
excluded on these grounds were ineligible on account of competing, intensive care-
based, studies. 
 
Establishing feasible recruitment for registered trials during first wave 
Using publicly available UK government data of the numbers of patients with COVID-
19 admitted to English hospitals during the first wave between March 17 and August 
5, 2020,14 and the recruitment rate (with 95% confidence interval (CI) for one sample 
proportion with continuity correction) from the aforementioned observational study, 
we estimated a maximum bound for the accumulated feasible recruitment during that 
time. Simultaneously, we used the estimated cumulative number of infected cases in 
England by 12 July provided by MRC Biostatistics Unit at the University of 
Cambridge15 to calculate an approximate hospitalisation rate in England among 
COVID-19 infections. We based our estimates on data from centres in England as 
the infection rate estimates were more reliable, hospitalisation criteria were different 
in Wales,14 and the 5 hospitals included in this study are all from England. 
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Patient and public involvement 
This was a time-critical study in response to a Public Health Emergency of 
International Concern. Patients or the public were not involved in the design, 
conduct, or reporting of this research. 
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Results 
 
Establishing recruitment targets to registered trials during first wave 
Clinical trial registry data were downloaded on July 12, 2020; 28 interventional 
studies were included in our analysis of those registered in England. 22 (78%) were 
academically sponsored, 5 (18%) were non-academically sponsored and 1 (4%) was 
mixed. The first registration date of a COVID-19 treatment trial in England was 
March 22; the earliest registered start date was March 12. Analysis of recruitment 
targets for each trial revealed that 46,154 participants would be required to complete 
recruitment to all studies in England (Table 1): 17,012 people are required for trials 
of prophylactic drugs to prevent COVID-19, while 29,142 are needed for those 
treating established COVID-19 (Table 1). The median (IQR) treatment trial 
recruitment target was 195 (50-793). 
 
By contrast, the global situation is such that 1,107 registered interventional trials 
were ongoing or completed, requiring 566,872 patients to be randomised to allow 
their completion; 306,426 of these are needed for trials of COVID-19 treatments 
(Figure 1A and 1B). These trials are geographically clustered in China, North 
America and Europe (Figure 1C).  
 
Observational study of clinical trial enrolment 
From March 27 to May 22, 2020 a total of 2,082 consecutive patients were included 
across the 5 sites (Table 2). Age and sex data were available for 1,971 patients: the 
median (IQR) age was 71 (58-82) and 56.2% were male. Across the four trials, 430 
(20.7%, 95% CI [18.95%, 22.47%]) proceeded to randomisation.  
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Of the remaining 1,652 patients, 82 (3.9%) declined participation, 363 (17.4%) were 
medically fit for discharge, 153 (7.3%) were receiving end of life care and 106 (5.1%) 
were mechanically ventilated at the time of screening. In 699 (33.6%) patients, the 
screening or treating physician determined that the potential participant should not 
be enrolled on account of clinical grounds or trial exclusion criteria.  
 
Establishing feasible recruitment for registered trials during first wave 
 
By combining these observed recruitment rates with publicly reported hospitalisation 
data (between March 17, and July 12, 2020), we estimated a maximum upper bound 
for the accumulated feasible recruitment for registered trials of COVID-19 treatments 
in England during the first wave (Figure 2).  
 
The estimated number of cumulative infected cases by 12 July reported by MRC 
Biostatistics Unit is 4.67 million with a 95% credible interval [3.76, 6.04]. Combined 
with the number of cumulative admitted patients in England by 12 July from 
government data (i.e. 111,037 hospital admissions), this gives an approximate 
hospitalisation rate 2.38% [1.84%, 2.95%] in England during the first wave. 
 
Our analysis indicates that by July 12th, 6,158 patients might still be needed to meet 
the total recruitment targets for currently recruiting clinical trials. If considering 
uncertainty in recruitment rate estimate reflected by 95% CI [18.95%, 22.47%], 
4,192-8,100 patients might be required to meet recruitment target. Assuming the 
recruitment rate 20.7%, this implies that 29,749 hospitalised patients would need to 
 - 15 - 
be screened for these trials to complete recruitment. With the approximate 
hospitalisation rate 2.38% in England as observed in the first wave, this would 
require 1.249 million patients to be infected.  
 
With the daily infection rate for UK estimated to be 3,310 (95% credible interval  
[2440, 4460]) on 12 July,15 it is highly unlikely such a large number of 
hospitalisations would occur unless there is an increase in the infection numbers (or 
a second wave). Indeed, incorporating hospitalisation data to August 5, 2020, shows 
minimal progress toward the recruitment target, assuming no new trials were 
approved after July 12, 2020 (Figure 2B).   
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Discussion 
 
We found that the proliferation of clinical trials1 in response to the first wave of the 
COVID-19 pandemic in England required 29,142 participants to complete enrolment 
to those registered with a trials database. Globally, 306,426 participants are required 
to meet recruitment targets for trials of treatments of COVID-19. Meanwhile, in our 
multicentre prospective observational cohort study of patients admitted to hospital 
with laboratory-confirmed COVID-19, 79.3% of potential participants were not 
recruited to a clinical trial; the reasons for excluding patients were varied and clarify 
the challenges faced in both general hospitals and well-resourced centres 
experienced in experimental medicine. Our experience is consistent with the general 
literature on clinical trial recruitment where many factors have been posited to 
contribute to heterogeneity of recruitment.16 With 111,037 people hospitalised in 
England between March 17 and July 12, 2020, our net recruitment rate suggests that 
22,985 (21,042-24,950 if taking into account uncertainty in recruitment rate estimate 
by random errors) would have been potentially suitable for selection in the first wave.  
However, this is clearly an overestimate, given that it would require each of these 
individuals to be hospitalised in geographical locations where medical centres were 
undertaking these trials. In the first wave, most general clinical trials infrastructure 
was mothballed for normal activity and therefore easily seconded towards COVID-19 
and this may not be the case in subsequent “waves”. It must also be recalled that 
most recruitment in the first wave was undertaken as hospitals were actively 
reconfiguring services. A stable hospital infrastructure may positively impact on ease 
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of delivery in the future.  Nevertheless, unless there is a second wave it is highly 
unlikely that the total recruitment target will be met in any reasonable timeframe. 
 
Strengths of our study are that our analyses of registry and population databases 
utilised the largest and most robust data available. Meanwhile, our observational 
study applied a large cohort size, prospective data acquisition, and recorded detailed 
reasons for excluding patients. By using both secondary and tertiary care centres, 
we believe our results are generalisable to other hospitals in the UK. Also, by 
following studies with minimal selection criteria, particularly in the RECOVERY trial, 
we reduced the chance of underestimating trial recruitment. Our study does have 
limitations. First, our predictions were based on registry data for studies based in 
England alone; we did not include the numbers of participants required to be 
recruited into multinational trials in which the English centres were involved. The 
result is that we have likely underestimated the trial recruitment target for England 
and, by extension, the gap between this and the number of participants available. 
Second, although we used hospitalisation data from 17 March 2020, as this was the 
time the UK government commenced public reporting of COVID-19 admissions, all 
trials included in our registry analysis were not recruiting at that stage; the earliest 
start date for a trial registered in England was March 12, 2020, but the last trial start 
date was not until July 7, 2020. In this sense, using cumulative number of admitted 
patients in our prediction is optimistic. Third, we only included the two registry 
datasets in most widespread use, and so may have further underestimated the 
number of studies and participants required.  Fourth, the 95% CI for recruitment rate 
estimate only reflects the uncertainty due to random errors in the data, it does not 
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consider the uncertainty due to unrepresentativeness of data from the 5 hospital 
centres in our study. Finally, although we illustrate the scale of trial recruitment 
required globally, the populations tested may not be representative of, or translatable 
to, international cohorts. 
 
Our study is the first to characterise the suitability and barriers for trial enrolment for 
a complete cohort of hospitalised patients with COVID-19. Results of trials published 
to date convey a different message: interventional studies of lopinavir and 
remdesivir, for example, have recruitment rates ranging from 55.7%-96.0%.2-4 This 
difference is most likely explained by the different denominators used in our 
calculations: the consort diagrams in clinical trials are unlikely to include every single 
patient hospitalised with a positive test. Instead, our results align with or exceed 
other centres, such as the 10% recruitment rate to RECOVERY.9 During the 2013-16 
Ebola Virus Disease (EVD) epidemic in west Africa, most clinical trials during that 
crisis either started too late to enrol sufficient case numbers or were simply unable to 
reach their recruitment targets.17 Our study shows that trials in England started 
recruiting relatively quickly, however many are highly unlikely to recruit on time; we 
conclude that starting early is important but not enough to ensure recruitment targets 
are met. Finally, it is notable that our calculated hospitalisation rate of 2.38% is lower 
than that observed in Wuhan,18 which if applied to the UK age structure,19 is 
equivalent to approximately 5.8%. 
 
The disparity between the realistic recruitment rates and high requirements we report 
leads us to conclude that the scientific community should be increasingly selective in 
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the number, size and design of clinical trials deployed in the COVID-19 pandemic; 
our findings have meaning for those planning single trials, and those strategizing the 
national response. Potential solutions include practical changes to trial design, for 
instance capturing patients earlier in their disease path, and adopting dynamic and 
adaptive trial designs.20 Yet, such measures are unlikely to bridge the currently 
estimated large recruitment gap. Instead, it may be necessary for healthcare 
authorities and policy makers to foster more academic cooperation to prioritise 
compounds, prevent duplication and, perhaps more radically, perform real-time 
meta-analyses of ongoing trials of the same therapies and provide stop/go 
recommendations across trials to rationalise treatment and prevent multiple studies 
delaying reporting.21 Indeed, proposals have been forthcoming for mechanisms by 
which data from different trials might be shared and analysed in a robust and 
scientifically meaningful way.22 These conclusions are not dissimilar to reflections 
from the Ebola pandemic, when there was a strong call for strengthening and 
coordinating research efforts in response to outbreaks of emerging infectious 
diseases.23 24 For planning future trials and deriving realistic recruitment targets, real-
time tracking of the pandemic, as data accumulate over time, is essential to plan 
research in response of an emerging epidemics outbreak. The Medical Research 
Council (MRC) Biostatistics Unit regularly nowcast and forecast COVID-19 infections 
and deaths.15 This information feeds directly to SAGE sub-group, Scientific 
Pandemic Influenza sub-group on Modelling (SPI-M) and to regional PHE teams. 
This same data could be used to establish realistic recruitment trends to inform, 
monitor and coordinate research efforts both for treatment and prevention trials.  
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Multiple questions remain for future research. In particular, it remains unclear how 
relaxing of non-pharmacological interventions will affect transmission rates, and 
therefore the achievability of remaining recruitment to these trials. It is also unknown 
how a second wave would evolve, and whether more or fewer people will develop 
the illness than was seen in the first. Nonetheless, we conclude that clinical trialists 
and healthcare authorities must consider the recruitment challenges when 
determining the feasibility of clinical trials in a second wave and urgently rationalise 
those currently active. 
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Figure legends 
 
Figure 1. The proliferation of global clinical trials in response to COVID-19. A: 
cumulative number of enrolling studies registered with clinicaltrials.gov or ISRCTN 
until Jul 12, 2020, subdivided by those testing drugs for COVID-19 treatment and 
prevention. B: cumulative number of participants required to meet recruitment targets 
for registered clinical trials. C: geographical distribution of COVID-19 clinical trials. 
 
Figure 2. Feasibility of achieving target recruitment in England for COVID-19 
interventional studies. A: cumulative number of enrolling studies in England 
registered with clinicaltrials.gov or ISRCTN until July 12, 2020, subdivided by those 
testing drugs for COVID-19 treatment and prevention. B: cumulative number of 
participants required to meet recruitment targets for registered COVID-19 treatment 
trials until July 12, 2020, and predicted number of patients whom would have been 
eligible for randomisation (grey shaded area represents point-wise 95% confidence 
band for the predictive cumulative number of eligible patients using the lower and 
upper value of 95% confidence interval for the recruitment rate estimate with 
continuity correction). The reduction in the infection rate in England means that the 
recruitment target at July 12 is unlikely to be reached unless there is a second wave; 
further illustrated by extending hospitalisation data to August 5, 2020. 
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Tables 
 
 
 Number of Trials Number of Participants 
Global Trials   
Prevention 172 260,446 
Treatment 935 306,426 
Total 1,107 566,872 
UK Multi-National and 
National Trials  
  
Prevention 11 97,272 
Treatment 38 44,362 
Total 49 141,634 
England Trials    
Prevention 8 17,012 
Treatment 20 29,142 
Total 28 46,154 
 
Table 1: Summary of number of trials and required numbers of participants  
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 RECOVERY COMBIN
ATION* 
C19-
ACS 
SIMPLE Total 
Total screened per 
centre  
281 83 415 Total 
(779) 
445 784 74 2,082 
Number recruited (%) 35 (12.5) 16 
(19.3) 
185 
(44.6) 
236 
(30.3) 
124 
(27.9) 
56 (7.1) 14 (18.9) 430 
(20.7) 
Refused participation 
(%) 
10 (3.6) 19 
(22.9) 
16 (3.9) 45 (5.8) 8 (1.8) 29 (3.7) 0 (0.0) 82 (3.9) 
Clinical grounds/trial 
exclusion criteria(%) 
83 (29.5) 15 
(18.1) 
40 (9.6) 138 
(17.7) 
167 
(37.5) 
365 
(46.6) 
29 (39.2) 699 
(33.6) 
Lacked capacity (%) 22 (7.8) 0 (0.0) 1 (0.2) 23 (3.0) 16 (3.6) 98 (12.5) 0 (0.0) 137 
(6.6) 
Mechanical ventilation 
(%) 
37 (13.2) 7 (8.4) 0 (0.0) 44 (5.6) 7 (1.6) 48 (6.1) 7 (9.5) 106 
(5.1) 
Drug interactions (%) 12 (4.3) 2 (2.4) 0 (0.0) 14 (1.8) 2 (0.4) 1 (0.1) 0 (0.0) 17 (0.8) 
Medically fit for 
discharge (%) 
55 (19.6) 14 
(16.9) 
77 
(18.6) 
146 
(18.7) 
65 (14.6) 136 
(17.3) 
16 (21.6) 363 
(17.4) 
Palliative care (%) 19 (6.8) 7 (8.4) 61 
(14.7) 
87 
(11.2) 
8 (1.8) 51 (6.5) 7 (9.5) 153 
(7.3) 
Not approached or 
considered (%) 
8 (2.8) 3 (3.6) 35 (8.4) 46 (5.9) 48 (10.8) 0 (0.0) 1 (1.4) 95 (4.6) 
Total not recruited 
(%) 
246 
(87.5) 
67 
(80.7) 
230 
(55.4) 
543 
(69.7) 
321 
(72.1) 
728 
(92.9) 
60 (81.1) 1,652 
(79.3) 
 
Table 2: screening data for 2,082 consecutive patients with laboratory-confirmed 
SARS-CoV-2 admitted to one of 5 centres. *centre screened concurrently to both 
RECOVERY and SIMPLE: moderate and severe trials. 
 
 
 
 
 
 
 
 
 - 27 - 
References 
 
1. Thorlund K, Dron L, Park J, et al. A real-time dashboard of clinical trials for 
COVID-19. The Lancet Digital Health 2020;2(6):e286-e87. doi: 
10.1016/S2589-7500(20)30086-8 
2. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized 
with Severe Covid-19. New England Journal of Medicine 2020;382(19):1787-
99. doi: 10.1056/NEJMoa2001282 
3. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-
19 — Preliminary Report. New England Journal of Medicine 2020 doi: 
10.1056/NEJMoa2007764 
4. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a 
randomised, double-blind, placebo-controlled, multicentre trial. The Lancet 
2020;395(10236):1569-78. doi: 10.1016/S0140-6736(20)31022-9 
5. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in 
Hospitalized Patients with Covid-19. New England Journal of Medicine 
2020;382(25):2411-18. doi: 10.1056/NEJMoa2012410 
6. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a 
treatment of COVID-19: results of an open-label non-randomized clinical trial. 
International Journal of Antimicrobial Agents 2020:105949. doi: 
https://doi.org/10.1016/j.ijantimicag.2020.105949 
7. Zhang C, Wu Z, Li J-W, et al. Cytokine release syndrome in severe COVID-19: 
interleukin-6 receptor antagonist tocilizumab may be the key to reduce 
mortality. International Journal of Antimicrobial Agents 2020;55(5):105954. 
doi: https://doi.org/10.1016/j.ijantimicag.2020.105954 
 - 28 - 
8. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients 
with Covid-19 — Preliminary Report. New England Journal of Medicine 2020 
doi: 10.1056/NEJMoa2021436 
9. Wilkinson E. RECOVERY trial: the UK covid-19 study resetting expectations for 
clinical trials. BMJ 2020;369:m1626. doi: 10.1136/bmj.m1626 
10. Norrie JD. Remdesivir for COVID-19: challenges of underpowered studies. The 
Lancet 2020;395(10236):1525-27. doi: 10.1016/S0140-6736(20)31023-0 
11. Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to 
Clinical Improvement in Patients With Severe and Life-threatening COVID-19: 
A Randomized Clinical Trial. JAMA 2020;324(5):460-70. doi: 
10.1001/jama.2020.10044 
12. Xu S, Li Y. Beware of the second wave of COVID-19. The Lancet 
2020;395(10233):1321-22. doi: 10.1016/S0140-6736(20)30845-X 
13. Petersen E, Koopmans M, Go U, et al. Comparing SARS-CoV-2 with SARS-CoV 
and influenza pandemics. The Lancet Infectious Diseases  doi: 
10.1016/S1473-3099(20)30484-9 
14. Publich Health England. Coronavirus (COVID-19) in the UK 2020 [Available 
from: https://coronavirus.data.gov.uk/healthcare] accessed August 5 2020. 
15. MRC Biostatistics Unit. COVID-19: nowcast and forecast 2020 [Available from: 
https://www.mrc-bsu.cam.ac.uk/now-casting/report-on-nowcasting-and-
forecasting-6th-august-2020/] accessed August 14 2020. 
16. Thoma A, Farrokhyar F, McKnight L, et al. Practical tips for surgical research: 
how to optimize patient recruitment. Can J Surg 2010;53(3):205-10. 
[published Online First: 2010/05/29] 
 - 29 - 
17. Rojek A, Horby P, Dunning J. Insights from clinical research completed during 
the west Africa Ebola virus disease epidemic. The Lancet Infectious Diseases 
2017;17(9):e280-e92. doi: 10.1016/S1473-3099(17)30234-7 
18. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus 
disease 2019: a model-based analysis. The Lancet Infectious Diseases 
2020;20(6):669-77. doi: 10.1016/S1473-3099(20)30243-7 
19. Office of national statistics. Old age structure variant - UK population in age 
groups 2018 [Available from: 
https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigrati
on/populationprojections/datasets/tablel21oldagestructurevariantukpopulationi
nagegroups] accessed May, 28 2020. 
20. Brueckner M, Titman A, Jaki T, et al. Performance of different clinical trial 
designs to evaluate treatments during an epidemic. PLOS ONE 
2018;13(9):e0203387. doi: 10.1371/journal.pone.0203387 
21. Bauchner H, Fontanarosa PB. Randomized Clinical Trials and COVID-19: 
Managing Expectations. JAMA 2020;323(22):2262-63. doi: 
10.1001/jama.2020.8115 
22. Petkova E, Antman EM, Troxel AB. Pooling Data From Individual Clinical Trials 
in the COVID-19 Era. JAMA 2020 doi: 10.1001/jama.2020.13042 
23. World Health Organisation. Report of the Ebola Interim Assessment Panel - May 
2015, 2015. 
24. National Academies of Sciences E, Medicine. Integrating Clinical Research into 
Epidemic Response: The Ebola Experience. Washington, DC: The National 
Academies Press 2017. 
 - 30 - 
 
